NCT01100502 2021-05-14A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)Seagen Inc.Phase 3 Completed329 enrolled 15 charts